Evaluation of the prophylaxis and treatment of COVID-associated coagulopathy

Figures & data

Fig. 1 Characteristic features of COVID-19-associated coagulopathy

Fig. 2 Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of different D-dimer cut-off levels for predicting VTE in COVID-19 patients [19]

Fig. 3 ISTH algorithm for management of coagulopathy in COVID-19 [33]. Algorithm for the management of coagulopathy in COVID‐19 based on simple laboratory markers. * The list of markers is given in decreasing order of importance. ** Performing fibrinogen assays may not be feasible in many laboratories, but monitoring the levels can be helpful after patient admission. *** Although a specific cut‐off cannot be defined, a three‐ to four‐fold increase in D‐dimer values may be considered significant. Anyone of the values in this table may be regarded as significant

Fig. 4 Emory protocol—April 22, 2020

Fig. 5 Cleveland Clinic thrombosis risk assessment [36]

Fig. 6 Coagulation cascade

Coronavirus (COVID-19) clinical guidance repository. AAMC. 2020. https://www.aamc.org/coronavirus-covid-19-clinical-guidance-repository. Accessed 9 May 2020

 Google Scholar

Mousavi S, Moradi M, Khorshidahmad T, Motamedi M. Anti-inflammatory effects of heparin and its derivatives: a systematic review. 2020.

 Google Scholar

Wang J, Hajizadeh N, Moore EE, McIntyre RC, Moore PK, Veress LA, Yaffe MB. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series. J Thromb Haemost. 2020. https://doi.org/10.1111/jth.14828. (Epub ahead of print).

 Web of Science ®Google Scholar

Availability of data and materials

Data sharing is not applicable to this article, as no datasets were generated or analyzed during the current study.